HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) | RFA NS 21 016

Opportunity Information: Apply for RFA NS 21 016

The HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) funding opportunity (RFA-NS-21-016) is a National Institutes of Health discretionary grant designed to help research teams get organized and technically ready for a larger, subsequent translational research application focused on non-addictive pain therapeutics. The core purpose of this FOA is not to fund a full development program on its own, but to support a focused, two-year exploratory/planning phase that produces the key feasibility evidence, team structure, and foundational data needed to credibly compete for the follow-on HEAL team award mechanism referenced in the announcement: RFA-NS-21-015 (U19 Clinical Trial Not Allowed). In practical terms, this R34 is positioned as a stepping-stone that should reduce risk and uncertainty before a group commits to the scale and coordination required by a U19 team research effort.

A central theme of the opportunity is team-building for early translational analgesic development in the small molecule and biologics space. Applicants are expected to use the award period to assemble and strengthen a multidisciplinary research team, fill capability gaps, and recruit additional collaborators where needed. The FOA makes it clear that the proposed aims should be limited in scope and targeted toward producing technically qualifying results rather than attempting to complete late-stage development work. The deliverables should demonstrate that the team is functional and aligned, and that the overall concept is realistic enough to justify a larger, more integrated project later.

On the science side, the FOA emphasizes generating preliminary evidence that connects a proposed therapeutic target to a specific pain indication. A competitive application should lay out a clear strategy for collecting initial data that supports the biological and translational rationale: showing that the putative target is meaningfully linked to the pain condition of interest and that modulating the target (for example, inhibiting or activating its activity, depending on the hypothesis) is likely to produce beneficial outcomes for the disease or condition. The goal is to move beyond a general idea and into a substantiated, testable case that the target and approach are worth advancing. While the FOA does not require applicants to complete a full preclinical-to-clinic package, it expects enough rigor to justify the hypothesis and to demonstrate feasibility and validity of the approach.

As indicated by the title and the mechanism, clinical trials are not allowed under this R34. That limitation signals that the work should remain in the planning and early translational stage, such as target validation, early proof-of-concept experiments, assay development, establishing collaborative workflows, and other preparatory activities that enable the next phase. The emphasis is on building the technical and organizational foundation that a later, larger translational program would rely on.

In terms of structure and funding parameters, this is an NIH grant (Funding Instrument Type: Grant) with an award ceiling listed as $500,000. The project period is described as two years, consistent with the R34 exploratory/planning intent. The opportunity was created on March 11, 2021, and the original closing date is listed as May 18, 2021. The announcement is associated with multiple CFDA numbers (93.121, 93.213, 93.242, 93.273, 93.846, 93.853, 93.865, 93.866, 93.867), reflecting NIH’s multi-institute footprint and the broader HEAL Initiative context.

Eligibility is broad and includes many common applicant types across government, academia, nonprofit, and industry. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofits with and without 501(c)(3) status (excluding higher education institutions in that nonprofit category); for-profit organizations other than small businesses; small businesses; and other entities. The FOA also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), eligible federal agencies, faith-based or community-based organizations, Hispanic-serving institutions, historically Black colleges and universities (HBCUs), Indian/Native American tribal governments other than federally recognized, non-U.S. entities (foreign organizations), regional organizations, tribally controlled colleges and universities (TCCUs), and U.S. territories or possessions. This wide eligibility signals an intent to encourage diverse, cross-sector teams and broaden participation in non-addictive analgesic development.

Overall, this FOA is best understood as a targeted planning and de-risking mechanism within the HEAL Initiative pipeline for non-addictive pain therapeutics. A strong application would clearly explain the pain indication and target rationale, specify what initial data will be generated to connect the target to the indication, and show how the team will be formed or strengthened to execute the work. The expected endpoint is a well-justified, team-ready foundation that directly enables a competitive U19 Team Research application for initial translational efforts in small molecules or biologics, without proposing or conducting a clinical trial during the R34 period.

• The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.242, 93.273, 93.846, 93.853, 93.865, 93.866, 93.867.
• This funding opportunity was created on 2021-03-11.
• Applicants must submit their applications by 2021-05-18. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 21 016

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: